Screener
Spyre Therapeutics, Inc. SYRE Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Other (expense) income, net | (30,359) | 2,286 |
| Total other (expense) income | (23,364) | 8,779 |
| Loss before income tax expense | (69,005) | (44,788) |
| Income tax benefit | — | 15 |
| Net loss | $(69,005) | $(44,773) |
| Net loss per share, basic and diluted, Series A Preferred Stock | $(29.66) | $(23.95) |
| Weighted-average Series A non-voting convertible preferred stock outstanding, basic and diluted | 346,045 | 346,045 |
| Net loss per share, basic and diluted, Series B Preferred Stock | $(29.66) | $(23.95) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s income tax?
- Spyre Therapeutics, Inc. (SYRE) reported income tax of $0 in Q1 2026.
- How has Spyre Therapeutics, Inc.'s income tax changed year-over-year?
- Spyre Therapeutics, Inc.'s income tax increased by 100.0% year-over-year, from -$15K to $0.
- What is the long-term trend for Spyre Therapeutics, Inc.'s income tax?
- Over 3 years (2021 to 2025), Spyre Therapeutics, Inc.'s income tax has grown at a -52.6% compound annual growth rate (CAGR), from $141K to -$15K.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Spyre Therapeutics, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude